MCID: PYD001
MIFTS: 49

Pyoderma Gangrenosum malady

Categories: Rare diseases, Skin diseases, Bone diseases

Aliases & Classifications for Pyoderma Gangrenosum

About this section
Sources:
11Disease Ontology, 13DISEASES, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 39MeSH, 40MESH via Orphanet, 48NIH Rare Diseases, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Pyoderma Gangrenosum:

Name: Pyoderma Gangrenosum 11 48 54 50 39 13 68

Characteristics:

Orphanet epidemiological data:

54
pyoderma gangrenosum:
Prevalence: 1-9/100000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/1000000 (Worldwide); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy

Classifications:



External Ids:

Disease Ontology11 DOID:8553
ICD1030 L88
ICD9CM32 686.01
MeSH39 D017511
SNOMED-CT62 74578003
Orphanet54 ORPHA48104
MESH via Orphanet40 D017511
UMLS via Orphanet69 C0085652
ICD10 via Orphanet31 L88

Summaries for Pyoderma Gangrenosum

About this section
NIH Rare Diseases:48 Pyoderma gangrenosum is a rare, destructive inflammatory skin disease of which a painful nodule or pustule breaks down to form a progressively enlarging ulcer. Lesions may occur either in the absence of any apparent underlying disorder or in association with other diseases, such as ulcerative colitis, Crohn's disease, polyarthritis (an inflammation of several joints together), gammopathy, vasculitis, leukemia, and other conditions. Each year in the United States, pyoderma gangrenosum occurs in about 1 person per 100,000 people. Pyoderma gangrenosum belongs to a group of autoinflammatory skin diseases called neutrophilic dermatoses. Neutrophils are a type of white blood cell or leukocyte which form an early line of defense against bacterial infections. Ulcerations associated with pyoderma gangrenosum may occur after trauma or injury to the skin, a process called pathergy. Treatment involves wound care and the use of anti-inflammatory agents, including antibiotics, corticosteroids, immunosuppressants, and biologics.  Last updated: 8/15/2016

MalaCards based summary: Pyoderma Gangrenosum is related to burns and skin disease, and has symptoms including skin rash, pulmonary infiltrates and myositis. An important gene associated with Pyoderma Gangrenosum is PSTPIP1 (Proline-Serine-Threonine Phosphatase Interacting Protein 1), and among its related pathways are Canonical NF-kappaB pathway and Immune response_MIF-mediated glucocorticoid regulation. The drugs clofazimine and sulfapyridine pwdr have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and bone, and related mouse phenotypes are hematopoietic system and skeleton.

Wikipedia:71 Pyoderma gangrenosum is a condition that causes tissue to become necrotic, causing deep ulcers that... more...

Related Diseases for Pyoderma Gangrenosum

About this section

Diseases related to Pyoderma Gangrenosum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 249)
idRelated DiseaseScoreTop Affiliating Genes
1burns30.6CXCL8, TNF
2skin disease30.2CXCL8, TNF
3microscopic colitis29.8CXCL8, NOD2, TNF
4rheumatoid arthritis29.8CXCL8, IL1R1, ITGB2, TNF
5pyogenic sterile arthritis, pyoderma gangrenosum, and acne12.4
6pyogenic arthritis, pyoderma gangrenosum and acne12.3
7pyoderma gangrenosum-acne-suppurative hidradenitis syndrome12.1
8pyoderma11.7
9crohn's disease11.5
10ileocolitis11.1
11polydactyly, postaxial, types a1 and b11.1
12zori stalker williams syndrome10.6IL1R1, PSTPIP1
13astrocytoma10.5IL1R1, TNF
14acneiform dermatitis10.5NOD2, TNF
15crohn's colitis10.5NOD2, TNF
16colitis10.5
17basidiobolomycosis10.5CXCL8, TNF
18maligant granulosa cell tumor of ovary10.5CXCL8, TNF
19phlyctenulosis10.5NOD2, TNF
20primary biliary cirrhosis10.5IL1R1, TNF
21ulcerative colitis10.5
22addison's disease10.5CXCL8, TNF
233-alpha hydroxyacyl-coa dehydrogenase deficiency10.5CXCL8, TNF
24pasteurellosis10.5CXCL8, TNF
25uterus carcinoma in situ10.5CXCL8, PSTPIP1
26t-cell lymphoma 1a10.5CXCL8, TNF
27spondylohypoplasia, arthrogryposis and popliteal pterygium10.5NOD2, TNF
28paraphimosis10.5CXCL8, TNF
29qualitative platelet defect10.5CXCL8, TNF
30capillary lymphangioma10.4NOD2, TNF
31orbital lymphangioma10.4CXCL8, TNF
32pseudoretinitis pigmentosa10.4CXCL8, TNF
33female reproductive system disease10.4NOD2, TNF
34keloids10.4IL1R1, TNF
35gonococcal synovitis10.4ITGB2, TNF
36prostate calculus10.4CXCL8, NOD2
37paraneoplastic polyneuropathy10.4CXCL8, TNF
38gastroduodenal crohn's disease10.4NOD2, TNF
39mechanical lagophthalmos10.4CXCL8, TNF
40leukoplakia10.4IL1R1, TNF
41inner ear cancer10.4CXCL8, TNF
42staphyloenterotoxemia10.4CXCL8, TNF
43acne10.4
44loin pain hematuria syndrome10.4ITGB2, TNF
45chromosome 9p deletion syndrome10.4NOD2, TNF
46accessory nerve disease10.4CXCL8, TNF
47arthritis10.4
48dementia - subcortical10.4CXCL8, TNF
49lacrimal system cancer10.3NOD2, TNF
50tibialis tendinitis10.3CXCL8, TNF

Graphical network of the top 20 diseases related to Pyoderma Gangrenosum:



Diseases related to pyoderma gangrenosum

Symptoms & Phenotypes for Pyoderma Gangrenosum

About this section

Human phenotypes related to Pyoderma Gangrenosum:

 64 54 (show all 17)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 skin rash64 hallmark (90%) HP:0000988
2 pulmonary infiltrates64 hallmark (90%) HP:0002113
3 myositis64 54 hallmark (90%) Very frequent (99-80%) HP:0100614
4 skin ulcer64 54 hallmark (90%) Very frequent (99-80%) HP:0200042
5 abnormal blistering of the skin64 54 typical (50%) Occasional (29-5%) HP:0008066
6 atrophic scars54 Frequent (79-30%)
7 rheumatoid arthritis54 Frequent (79-30%)
8 fever54 Very frequent (99-80%)
9 inflammation of the large intestine54 Frequent (79-30%)
10 arthralgia54 Very frequent (99-80%)
11 myelodysplasia54 Frequent (79-30%)
12 myalgia54 Very frequent (99-80%)
13 hypergammaglobulinemia54 Frequent (79-30%)
14 myeloid leukemia54 Frequent (79-30%)
15 papule54 Very frequent (99-80%)
16 skin vesicle54 Occasional (29-5%)
17 pustule54 Frequent (79-30%)

UMLS symptoms related to Pyoderma Gangrenosum:


cachexia, cancer pain, tumor pain, metastatic pain, breakthrough pain

MGI Mouse Phenotypes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053978.4IL1R1, ITGB2, MEFV, NLRP3, NOD2, PSTPIP1
2MP:00053907.9IL1R1, ITGB2, MEFV, NLRP3, NOD2, TNF
3MP:00053877.5IL1R1, ITGB2, MEFV, MMP10, NLRP3, NOD2

Drugs & Therapeutics for Pyoderma Gangrenosum

About this section

Drugs for Pyoderma Gangrenosum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Minocyclineapproved, investigationalPhase 322410118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
HMS2090D03
HSDB 3130
 
LMPK07000002
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline (USAN/INN)
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
NCGC00178854-01
NSC 141993
NSC141993
UNII-FYY3R43WGO
Vectrin (Hydrochloride)
minociclinum
minocycline
nchembio.559-comp1
2Anti-Infective AgentsPhase 321402
3Anti-Bacterial AgentsPhase 310884
4Pharmaceutical SolutionsPhase 3, Phase 27793
5
Tacrolimusapproved, investigationalPhase 21074104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
6Immunosuppressive AgentsPhase 212770
7Antirheumatic AgentsPhase 210627
8ImmunoglobulinsPhase 2, Phase 16045
9Calcineurin InhibitorsPhase 21597
10AntibodiesPhase 2, Phase 16045
11Antibodies, MonoclonalPhase 2, Phase 13795
12
Infliximabapproved378170277-31-3
Synonyms:
 
Ig gamma-1 chain C region
Remicade
13Dermatologic Agents5674
14Gastrointestinal Agents8109

Interventional clinical trials:

(show all 14)
idNameStatusNCT IDPhase
1Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot StudyUnknown statusNCT00203697Phase 3
2An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02326740Phase 3
3An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02315417Phase 3
4A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma GangrenosumTerminatedNCT02318914Phase 3
5Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma GangrenosumCompletedNCT01882504Phase 2
6A Phase II Open Label Study of Xilonix in Subjects With Pyoderma GangrenosumCompletedNCT01965613Phase 2
7Canakinumab for Pyoderma GangrenosumCompletedNCT01302795Phase 2
8Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's DiseaseCompletedNCT01233570Phase 2
9Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma GangrenosumRecruitingNCT02733094Phase 1, Phase 2
10Safety and Efficacy Study of Humira in Treatment of Pyoderma GangrenosumWithdrawnNCT00730717Phase 2
11Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma GangrenosumWithdrawnNCT00690846Phase 2
12Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic FactorsUnknown statusNCT00933296
13Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel DiseaseCompletedNCT00791557
14Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin DiseasesRecruitingNCT01952275

Search NIH Clinical Center for Pyoderma Gangrenosum

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: pyoderma gangrenosum

Genetic Tests for Pyoderma Gangrenosum

About this section

Anatomical Context for Pyoderma Gangrenosum

About this section

MalaCards organs/tissues related to Pyoderma Gangrenosum:

36
Skin, Neutrophil, Bone, Lung, T cells, Myeloid, Monocytes

Publications for Pyoderma Gangrenosum

About this section

Articles related to Pyoderma Gangrenosum:

(show top 50)    (show all 698)
idTitleAuthorsYear
1
An Unusual Association of Chronic Recurrent Multifocal Osteomyelitis, Pyoderma Gangrenosum, and Takayasu Arteritis. (28042129)
2017
2
Misdiagnosed Periocular Pyoderma Gangrenosum Requiring Ectropion Repair With Development of Second Lesion of Pyoderma Gangrenosum at Graft Site. (26934168)
2016
3
Double Jeopardy: Autoimmune Myelofibrosis with Pyoderma Gangrenosum. (27401951)
2016
4
Pyoderma gangrenosum and its syndromic forms: Evidence for a link with autoinflammation. (27106250)
2016
5
The diagnosis you wish you had never operated on: Pyoderma gangrenosum misdiagnosed as necrotizing fasciitis-a case report. (27875063)
2016
6
Life-threatening rituximab-induced pyoderma gangrenosum successfully treated with intravenous immunoglobulin. (27897446)
2016
7
Wegener's granulomatosis and pyoderma gangrenosum--rare causes of facial ulcerations. (27117096)
2016
8
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine. (27149138)
2016
9
Severe Bilateral Lower Extremity Pyoderma Gangrenosum. (27980702)
2016
10
Autoinflammation in pyoderma gangrenosum and its syndromic form PASH. (27943240)
2016
11
Intestinal BehAset's disease with pyoderma gangrenosum successfully treated with the combination therapy of adalimumab and glucocorticoids. (27142127)
2016
12
Post Surgical Pyoderma Gangrenosum in flap surgery: diagnostic clues and treatment recommendations. (27938245)
2016
13
Successful Treatment of Pyoderma Gangrenosum after Augmentation Mastopexy Using Vacuum Therapy. (27975008)
2016
14
Pyoderma gangrenosum misdiagnosed as a mucormycosis. (27444545)
2016
15
Total hip arthroplasty for femoral neck fracture with pyoderma gangrenosum patient: A case report. (28012329)
2016
16
Treatment of Pyoderma Gangrenosum - Retrospective Multicenter Analysis of 121 Patients. (27060666)
2016
17
Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study. (27502313)
2016
18
Hyperbaric Oxygen Therapy for the Adjunctive Treatment of Pyoderma Gangrenosum: A Case Report. (27192719)
2016
19
Intractable Postoperative Wounds Caused by Self-Inflicted Trauma in a Patient with Cutaneous Munchausen Syndrome Presenting as a Pyoderma Gangrenosum-Like Lesion. (27194978)
2016
20
Successful Treatment of Pyoderma Gangrenosum with Cryoglobulinemia and Hepatitis C. (27345376)
2016
21
Multiple Pyoderma Gangrenosum Ulcers Associated with Cocaine Abuse. (28003907)
2016
22
Pyoderma gangrenosum of the eyelid. (27085278)
2016
23
Facial Pyoderma Gangrenosum Presenting With Cranial Nerve VII Palsy and Cicatricial Ectropion. (27893584)
2016
24
Multifocal and refractory pyoderma gangrenosum: Possible role of cocaine abuse. (27250583)
2016
25
Pyoderma gangrenosum and necrotizing fasciitis-like opportunistic invasive cutaneous fungal infection. (27126743)
2016
26
Severe pyoderma gangrenosum in association with a flame burn. (27583260)
2016
27
Pyoderma Gangrenosum in the Urologist Clinic. (27867335)
2016
28
Pyoderma gangrenosum after trauma in a dog. (27108868)
2016
29
High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. (27502191)
2016
30
Successful treatment of large refractory pyoderma gangrenosum-like presentation of granulomatosis with polyangiitis with rituximab. (27126548)
2016
31
Pyoderma gangrenosum associated with mantle cell lymphoma. (27559522)
2016
32
Pyoderma gangrenosum in a caesarean wound following caesarean section with late occurrence of pyoderma gangrenosum of the breast. (27435999)
2016
33
Concomitant Pyoderma Gangrenosum and Erythema Nodosum in a Patient With Ulcerative Colitis. (27474109)
2016
34
Pyoderma Gangrenosum in a Patient With Hereditary Spherocytosis. (26711368)
2016
35
Pyoderma gangrenosum: A clinico-epidemiological study. (27549869)
2016
36
Cutaneous malakoplakia masquerading as pyoderma gangrenosum. (27524799)
2016
37
Pyoderma gangrenosum associated with alitretinoin therapy. (27051854)
2016
38
Pyoderma gangrenosum mimicking mediastinitis after cardiac surgery: a case study. (27286670)
2016
39
Pediatric pyoderma gangrenosum: is it just big wounds on little adults? (27916349)
2016
40
Postoperative Pyoderma Gangrenosum: AA Clinical Review of Published Cases. (27489052)
2016
41
Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. (27864925)
2016
42
Ocular pyoderma gangrenosum: A systematic review. (27836332)
2016
43
Pyoderma gangrenosum with spleen involvement. Review of the literature and case report. (27900062)
2016
44
Pyoderma Gangrenosum, Acne and Suppurative Hidradenitis Syndrome Treated with Granulocyte and Monocyte Adsorption Apheresis. (27384061)
2016
45
Pyoderma Gangrenosum-A New Manifestation of Wilson Disease? (27194899)
2016
46
Bullous Pyoderma Gangrenosum With Subungual Involvement Associated With Ulcerative Colitis. (27893467)
2016
47
Intralesional methotrexate as an adjuvant treatment for pyoderma gangrenosum: A case report. (27451930)
2016
48
Pyoderma gangrenosum with extensive pulmonary involvement. (27658239)
2016
49
Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis. (27799888)
2016
50
Extensive Pyoderma Gangrenosum Associated With Granulomatosis With Polyangiitis With Both Responsive to Rituximab. (27660945)
2016

Variations for Pyoderma Gangrenosum

About this section

Expression for genes affiliated with Pyoderma Gangrenosum

About this section
Search GEO for disease gene expression data for Pyoderma Gangrenosum.

Pathways for genes affiliated with Pyoderma Gangrenosum

About this section

Pathways related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 16)
idSuper pathwaysScoreTop Affiliating Genes
19.8NOD2, TNF
29.6CXCL8, TNF
39.6CXCL8, TNF
49.2ITGB2, NOD2, TNF
5
Show member pathways
9.1CXCL8, IL1R1, TNF
6
Show member pathways
9.1CXCL8, IL1R1, TNF
79.1CXCL8, IL1R1, TNF
89.1CXCL8, IL1R1, TNF
99.0CXCL8, ITGB2, TNF
109.0CXCL8, ITGB2, TNF
119.0CXCL8, ITGB2, TNF
128.6CXCL8, ITGB2, NLRP3, TNF
138.4CXCL8, IL1R1, ITGB2, TNF
14
Show member pathways
8.4CXCL8, IL1R1, NLRP3, NOD2, TNF
15
Show member pathways
8.2CXCL8, MEFV, NLRP3, NOD2, PSTPIP1, TNF
16
Show member pathways
7.6IL1R1, ITGB2, MEFV, NLRP3, NOD2, PSTPIP1

GO Terms for genes affiliated with Pyoderma Gangrenosum

About this section

Cellular components related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cell surfaceGO:00099868.6IL1R1, ITGB2, NOD2, TNF

Biological processes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 15)
idNameGO IDScoreTop Affiliating Genes
1detection of biotic stimulusGO:000959510.5NLRP3, NOD2
2positive regulation of interleukin-1 beta secretionGO:005071810.4NLRP3, NOD2
3positive regulation of interleukin-8 productionGO:003275710.4NOD2, TNF
4positive regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:004328010.4NLRP3, TNF
5positive regulation of type 2 immune responseGO:000283010.3NLRP3, NOD2
6positive regulation of NIK/NF-kappaB signalingGO:190122410.3NOD2, TNF
7embryonic digestive tract developmentGO:004856610.3CXCL8, TNF
8cellular extravasationGO:004512310.2ITGB2, TNF
9defense responseGO:000695210.1NLRP3, NOD2, TNF
10cellular response to lipopolysaccharideGO:00712229.9CXCL8, NLRP3, TNF
11negative regulation of inflammatory responseGO:00507289.9MEFV, MVK, NLRP3
12receptor internalizationGO:00316239.8CXCL8, ITGB2
13positive regulation of NF-kappaB transcription factor activityGO:00510929.4ITGB2, NLRP3, NOD2, TNF
14regulation of inflammatory responseGO:00507279.3IL1R1, NLRP3, NOD2
15inflammatory responseGO:00069548.5CXCL8, ITGB2, MEFV, NLRP3, PSTPIP1, TNF

Molecular functions related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1peptidoglycan bindingGO:00428349.8NLRP3, NOD2

Sources for Pyoderma Gangrenosum

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet